Daniele Piomelli

This inventor holds 25 USPTO granted patents and 9 published patent applications, plus 5 CIPO patents and 13 EPO patents. Top assignees: University of California, Università Degli Studi Di Parma, Fondazione Istituto Italiano Di Technologia. Active years: 1999-2020.

USPTO Granted Patents = 25 (Patent Applications = 9)

% Patents Active = 80.0

CIPO Patents = 5 (Patent Applications = 4)

EPO Patents = 13 (Patent Applications = 14)

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 75(Granted Patents)

Location History:

San Diego, CA (US) (1999 - 2011)
Oakland, CA (US) (2017)
Irvine, CA (US) (2002 - 2020)

Company Filing History:

18 out of 15,988

University of California

patents

8 out of 20

Università Degli Studi Di Parma

patents

7 out of 24

Fondazione Istituto Italiano Di Technologia

patents

4. 6 out of 6

Università Degli Studi Di Urbino "Carlo Bo"

patents

5. 5 out of 146

Fondazione Istituto Italiano Di Tecnologia

patents

6. 3 out of 24

Neurosciences Research Foundation, Inc.

patents

7. 3 out of 7

Universita Degli Studi Di Urbino

patents

8. 1 out of 94

Alma Mater Studiorum-Universitá Di Bologna

patents

9. 1 out of 962

The University of Chicago

patents

10. 1 out of 1

Universita Degl Studi Di Parma

patent

11. 2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2020

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10556892 - Piperazinyl methanone NAAA inhibitors (2020-02-11),

2. 10435355 - Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments (2019-10-08),

3. 10363237 - Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase (2019-07-30),

4. 10226452 - Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments (2019-03-12),

5. 10213416 - Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments (2019-02-26),

6. 9908848 - Amide derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors (2018-03-06),

7. 9828352 - Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) (2017-11-28),

8. 9828338 - Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors (2017-11-28),

9. 9822068 - Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments (2017-11-21),

10. 9745255 - Meta-substituted biphenyl peripherally restricted FAAH inhibitors (2017-08-29),

11. 9630914 - Multitarget FAAH and COX inhibitors and therapeutical uses thereof (2017-04-25),

12. 9428465 - Acid ceramidase inhibitors and their use as medicaments (2016-08-30),

13. 9353075 - Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA) (2016-05-31),

14. 9321743 - Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase (2016-04-26),

15. 9187413 - Peripherally restricted FAAH inhibitors (2015-11-17),

Title: Daniele Piomelli: A Leader in Innovative Pharmaceutical Research

Introduction

Daniele Piomelli, based in Irvine, CA, is a renowned inventor with a significant contribution to the field of pharmaceutical research, holding a total of 25 patents. His work focuses on developing novel therapeutic strategies to address complex medical conditions.

Latest Patents

Among his most recent innovations, Piomelli has developed a patent for Piperazinyl methanone NAAA inhibitors, which involves compositions and methods that modulate the activity of N-acylethanolamine acid amidase. This research aims to provide treatments for various pathological states, including pain, inflammatory conditions, and neurodegenerative disorders. Another significant patent revolves around inhibitors of the fatty acid amide hydrolase (FAAH) enzyme, featuring improved oral bioavailability and their potential use as medicaments.

Career Highlights

Piomelli's distinguished career includes insightful roles at prestigious academic institutions such as the University of California and Università degli Studi di Parma. Through his research, he has made groundbreaking advancements in understanding and treating conditions related to the endocannabinoid system.

Collaborations

Throughout his career, Daniele Piomelli has collaborated with notable scientists such as Marco Mor and Giorgio Tarzia. These collaborations have fostered a vibrant exchange of ideas that have propelled forward the field of cannabinoid research and pharmacology.

Conclusion

Daniele Piomelli continues to be a pivotal figure in pharmaceutical innovation, with a commitment to developing effective treatments for serious health conditions. His extensive patent portfolio reflects his dedication to advancing medical science for the betterment of society.